190A Stock Overview
A biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Chordia Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥307.00 |
| 52 Week High | JP¥930.00 |
| 52 Week Low | JP¥142.00 |
| Beta | 0 |
| 1 Month Change | 37.67% |
| 3 Month Change | -25.30% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 59.90% |
Recent News & Updates
Shareholder Returns
| 190A | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 20.4% | -1.7% | -1.5% |
| 1Y | n/a | 18.5% | 13.7% |
Return vs Industry: Insufficient data to determine how 190A performed against the JP Biotechs industry.
Return vs Market: Insufficient data to determine how 190A performed against the JP Market.
Price Volatility
| 190A volatility | |
|---|---|
| 190A Average Weekly Movement | 16.5% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 190A's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 190A's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Hiroshi Miyake | www.chordiatherapeutics.com |
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. The company was incorporated in 2017 and is based in Fujisawa, Japan.
Chordia Therapeutics Inc. Fundamentals Summary
| 190A fundamental statistics | |
|---|---|
| Market cap | JP¥20.78b |
| Earnings (TTM) | -JP¥1.83b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.4x
P/E RatioIs 190A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 190A income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥1.83b |
| Earnings | -JP¥1.83b |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
Jan 14, 2025
| Earnings per share (EPS) | -27.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 190A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 05:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chordia Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|